Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | TK1 | P04183 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22765060 | 0.87 | KDM4E (0.48) | KDM4ETSHRMEN1KMT2ANOS1 | |
| SCHEMBL15763710 | 0.86 | CDK5 (0.48) | KDM4ETSHRMEN1KMT2ANOS1 | |
| SCHEMBL22462003 | 0.85 | KDM4E (0.47) | KDM4ETSHRMEN1KMT2ANOS1 | |
| SCHEMBL22091499 | 0.85 | KDM4E (0.47) | KDM4ETSHRMEN1KMT2ANOS1 | |
| SCHEMBL22571148 | 0.84 | MEN1 (0.52) | KDM4ETSHRMEN1KMT2ANOS1 | |
| SCHEMBL18349588 | 0.84 | KDM4E (0.46) | KDM4ETSHRMEN1KMT2ANOS1 | |
| SCHEMBL10330296 | 0.83 | MEN1 (0.45) | KDM4ETSHRMEN1KMT2ATK1 | |
| SCHEMBL22083756 | 0.82 | KDM4E (0.47) | KDM4ETSHRMEN1KMT2ANOS1 | |
| SCHEMBL22571139 | 0.82 | KDM4E (0.47) | KDM4ETSHRMEN1KMT2ANOS1 | |
| SCHEMBL3457921 | 0.82 | MEN1 (0.50) | KDM4ETSHRMEN1KMT2ATK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-02 | — | — | US | disclosed |
| US-20230340008-A1 | BRIDGED NUCLEOSIDE AND NUCLEOTIDE USING SAME | JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF HEALTH SCIENCES (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230340008-A1 | BRIDGED NUCLEOSIDE AND NUCLEOTIDE USING SAME | JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF HEALTH SCIENCES (JP) | 2023-10-26 | — | — | US | disclosed |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| WO-2023177866-A1 | DECARBOXYLATIVE ACETOXYLATION USING MN(II) OR MN(III) REAGENT FOR SYNTHESIS OF 4'-ACETOXY- NUCLEOSIDE AND USE THEREOF FOR SYNTHESIS OF CORRESPONDING 4'-(DIMETHOXYPHOSPHORYL)METHOXY- NUCLEOTIDE | DICERNA PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023167094-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | 国立大学法人大阪大学 | 2023-09-07 | — | — | WO | disclosed |
| WO-2023149038-A1 | PHENOXAZINE DERIVATIVE AND DRUG DELIVERY SYSTEM FORMULATION USING SAME | 国立大学法人大阪大学 | 2023-08-10 | — | — | WO | disclosed |
| WO-2023131170-A1 | DOUBLE-STRANDED RNA HAVING NUCLEOTIDE ANALOG | 大睿生物医药科技(上海)有限公司 | 2023-07-13 | — | — | WO | disclosed |
| US-20230158469-A1 | DEVICES AND METHODS FOR SYNTHESIS | Twist Bioscience Corporation | 2023-05-25 | — | — | US | disclosed |
| US-20230158469-A1 | DEVICES AND METHODS FOR SYNTHESIS | Twist Bioscience Corporation | 2023-05-25 | — | — | US | disclosed |
| US-8524882-B2 | Method for deblocking of labeled oligonucleotides | Life Technologies Corporation (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524882-B2 | Method for deblocking of labeled oligonucleotides | Life Technologies Corporation (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120253028-A1 | METHOD FOR DEBLOCKING OF LABELED OLIGONUCLEOTIDES | Life Technologies Corporation (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120184724-A1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184724-A1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-8093372-B2 | Contacting with nucleophilic compound | Life Technologies Corporation (US) | 2012-01-10 | — | — | US | disclosed |
| US-7427675-B2 | Compounds and methods for the characterization of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427675-B2 | Compounds and methods for the characterization of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20080221303-A1 | Method for the Preparation of Peptide-Oligonucleotide Conjugates | FRUTAROM LTD. (IL) | 2008-09-11 | — | — | US | disclosed |
| US-20080221303-A1 | Method for the Preparation of Peptide-Oligonucleotide Conjugates | FRUTAROM LTD. (IL) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120253028-A1 | METHOD FOR DEBLOCKING OF LABELED OLIGONUCLEOTIDES | DCLRE1B, DDB1, DTYMK | KDM4E 3963/4885TSHR 2230/4885MEN1 3091/4885 |
| US-20230340008-A1 | BRIDGED NUCLEOSIDE AND NUCLEOTIDE USING SAME | SLC29A1, SLC29A2, PNP | KDM4E 4101/4885TSHR 3498/4885MEN1 1913/4885 |
| US-20080221303-A1 | Method for the Preparation of Peptide-Oligonucleotide Conjugates | VIP, PTMS, SSTR4 | KDM4E 4496/4885TSHR 241/4885MEN1 1038/4885 |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | STING1, IRF3, CGAS | KDM4E 3160/4885TSHR 2491/4885MEN1 4490/4885 |
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | POLRMT, DCLRE1B, RNGTT | KDM4E 3297/4885TSHR 2860/4885MEN1 3382/4885 |
| US-20120184724-A1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | RNMT, RNGTT, NSUN2 | KDM4E 3200/4885TSHR 2348/4885MEN1 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.